奇胺抑制MYC表达,可能改善双表达性淋巴瘤患者的存活率
Pengpeng Liu1, Xiaohang Hang2, Jianjun Li1
1Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University Chengdu 610041, Sichuan, China.
American journal of cancer research
|July 15, 2024
概括
奇达米德在治疗双表达性淋巴瘤 (DEL) 方面表现有前景,这种癌症的预后不佳. 这项研究发现,奇达胺抑制MYC通路,与标准疗法和干细胞移植相结合时改善结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 双表达性淋巴瘤 (DEL) 的预后不好.
- 在B细胞淋巴瘤中,希达胺 (HDAC抑制剂) 的疗效尚不清楚.
研究的目的:
- 为了研究基达胺在B细胞淋巴瘤中的疗效.
- 探索奇达胺与R-CHOP化疗结合用于DEL治疗的潜力.
主要方法:
- 抑制查和转录组分析确定了MYC表达作为奇达胺敏感性的预测指标.
- 对185名接受CR-CHOP (CHOP加奇达胺) 治疗的DEL患者进行了回顾性分析.
- 评估结果,包括应答率,无进展生存率 (PFS) 和总生存率 (OS),有和没有自身干细胞移植 (ASCT).
主要成果:
- 在B淋巴瘤细胞中,奇达胺的敏感性与MYC表达水平呈正相关性.
- 在LEL患者中,CR-CHOP治疗实现了80%的应答率.
- CR-CHOP显著改善了R-IPI ≤2.2的DEL患者的生存率.
- 与其他方案相比,将CR-CHOP与ASCT相结合,导致了优越的PFS和OS.
结论:
- 奇胺有效地抑制了B淋巴瘤细胞中的MYC通路.
- CR-CHOP是一种潜在有效的DEL治疗方法,可以改善治疗结果并减少复发.
- 结合CR-CHOP和ASCT为DEL患者提供了最有希望的生存益处.
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:06Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K